The IQVIA Pharma Deals Review of 2022 provides an insightful overview of deal activity in 2022, as well as an outlook for 2023.

Key information provided includes the following:

• Top M&A and partnership deals in 2022
• Deal activity by therapeutic area and development phase
• Deal value analysis of M&A, licensing and R&D deals
• Deal activity rankings of the top pharmaceutical companies

Report key highlights:

• Amid much market and economic turbulence, deal activity in the life sciences sector fell by 25% from 2021 to 2022, as many companies opted to pursue a wait and see approach and others were reluctant to accept discounted valuations.
• The volume of life science M&A deals announced in 2022 fell 30% from the frenetic pace of 2021 as pricing mismatches prevailed and the major players generally took a cautious approach to deal expenditure.
• After reaching a 5-year high in 2021, licensing activity in the life sciences sector dropped 25% from 2021 to 2022 as streamlined companies focused their partnering interests on high-growth opportunities and COVID-19-related licensing activity subsided.

Please fill in your details on the left to download the article.